Clinical Trials for Alzheimer's Disease
Tango is an Biogen-sponsored, phase II clinical trial that uses a monoclonal antibody designed to target tau in individuals with mild cognitive impairment or mild Alzheimer’s Disease. It is an 18-month, double-blind, placebo-controlled study that investigates this anti-tau compound to hopefully stop or slow down the progression of Alzheimer’s. This study is not currently enrolling.
Trailblazer is an 18-month clinical trial of a disease-modifying therapy for Alzheimer’s Disease, sponsored by Eli Lilly. The investigational drug is being tested for its safety and efficacy in removing amyloid plaques from the brains of those with early stages of Alzheimer’s. McLean is one of 61 sites across the United States and Canada involved in the study. This study is not currently enrolling.
Behavioral Symptoms of Alzheimer's Disease
Dronabinol is an in-patient pilot trial of a dronabinol-adjunctive treatment of agitation in Alzheimer’s Disease is being done to determine whether dronabinol is an effective and safe treatment for agitation in AD. Dronabinol is a synthetic drug version of tetrahydrocannabinol (THC), the main psychoactive ingredient in marijuana. This study is currently enrolling.
Caring for Behavioral Symptoms of Dementia (CBD)
CBD is an outpatient, open-label trial to assess the efficacy and safety of a high-CBD/low-THC sub-lingual solution as a treatment for anxiety in older adults with Alzheimer’s Disease. The solution has been developed by Staci Gruber, PhD, at McLean Hospital. Recruitment is estimated to begin in April 2020.
Electroconvulsive Therapy (ECT)
ECT-AD is a multisite, randomized, placebo-controlled inpatient trial aiming to determine the safety and efficacy of electroconvulsive therapy in the treatment of refractory agitation and aggression in patients with Alzheimer's Disease. This study is not currently enrolling.
Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression is a study examining changes in brain activity after the use of low-field magnetic stimulation (LFMS). LFMS involves a series of electromagnetic pulses to the brain, with no physical sensation associated with its usage. The study is investigating the antidepressant effects LFMS has on older adults with bipolar disorder who are currently depressed. We use fMRI to examine these brain changes. This study is currently enrolling.
GMDD is a three-year, longitudinal study of cognition and mood in older adults with and without the diagnoses of mood disorders. The study seeks to compare differences in cognition and functioning during the aging process in subjects with mood disorders and subjects without mood disorders. It is funded by the Rogers Family Foundation. This study is currently enrolling.
LIFT is a pilot study to assess the relationship between inflammation, attention/executive function, and treatment resistance in older adults with treatment refractory depression. The study will measure differences in attention/executive functioning in older adults with treatment resistant depression compared to age-matched healthy controls. This study is currently enrolling.